Meridia Weight Loss Drug
|
In November of 2009, the FDA announced that it was reviewing preliminary data from a study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo (sugar pill). Sibutramine is marketed as the prescription drug Meridia in the United States. Meridia (sibutramine) was approved in 1997 by the FDA for the management of obesity, including weight loss and maintenance of weight loss, in conjunction with a reduced calorie diet.
Meridia weight loss pills have been associated to potentially fatal and serious conditions.
Typically, the most common Meridia weight loss pill adverse effects include:
More side effects may include:
The preliminary study findings highlight the importance of avoiding the use of sibutramine in patients with a history of coronary artery disease (heart disease), congestive heart failure (CHF), arrhythmias, or stroke, as recommended in the current sibutramine labeling. Additionally, healthcare professionals should continue to evaluate the benefits and risks of sibutramine, taking into account individual patient medical histories. Consumers should talk to their healthcare professional about whether sibutramine is right for them.
**CLICK HERE FOR FREE CASE EVALUATION** |

